Table 1.

The baseline characteristics of all participants

	Meningeoma	Glioma	Healthy controls	HC vs BT	Meningeoma vs Glioma
	(n = 32)	(n = 27)	(n = 41)	p value	p value
Age (Mean ± SD)	55.37 ± 11.47	57.93 ± 9.93	55.80 ± 9.43	0.644	0.361
Gender				0.225	0.185
Male	10(31%)	14(52%)	21(51%)
Female	22(69%)	13(48%)	20(49%)
BMI	23.21 ± 2.33	22.88 ± 2.43	22.36 ± 2.14	0.131	0.595
Smoking				0.368	0.657
Absence	30 (93.8%)	26 (96.3%)	37 (90.2%)
Presence	2 (6.2%)	1 (3.7%)	4 (9.8%)
Drinking				0.600	0.517
Never	27 (84.4%)	22 (81.5%)	35 (85.4%)
<1 standard drink per day	2 (6.2%)	3 (11.1%)	5 (12.2%)
≥1 standard drink per day	3 (9.4%)	2 (7.4%)	1 (2.4%)
Hypertension				0.407	0.767
Negative	19 (59.4%)	15 (55.6%)	27 (65.9%)
Positive	13 (40.6%)	12 (44.4%)	14 (34.1%)
Diabetes				0.211	0.504
Negative	30 (93.8%)	24 (88.9%)	40 (97.6%)
Positive	2 (6.2%)	3 (11.1%)	1 (2.4%)
Hypercholesterolemia	5 (15.6%)	4 (14.8%)	2 (4.9%)	0.103	0.931
Excrement regularity				0.421	0.931
Yes	27 (84.4%)	23 (85.2%)	37 (90.3%)
No	5 (15.6%)	4 (14.8%)	4 (9.7%)
Tumor location				NA	0.004
Left	15	9	-
Right	17	10	-
Diffuse	0	8	-
Tumor maximum diameter (Mean ± SD, mm)	40.85 ± 13.45	44.5 ± 14.7	-	NA	0.785
TNM stage				NA	<0.0001
Stage I	30 (93.8%)	0 (0%)	-
Stage II	2 (6.2%)	0 (0%)	-
Stage III	(0%)	8 (29.6%)	-
Stage IV	(0%)	19 (70.4%)	-

HC: Healthy controls. BT: Brain tumors. BMI: Body mass index. SD: Standard deviation. TNM: Tumor-node-metastasis.